From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City.
Neurology. 2018 Jul 10;91(2):e123-e131. doi: 10.1212/WNL.0000000000005773. Epub 2018 Jun 8.
To implement a standardized approach to characterize neurologic outcomes among 12-month survivors in the Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA) trials.
Two multicenter trials enrolled children age 48 hours to 18 years who remained comatose after cardiac arrest (CA) occurring out-of-hospital (THAPCA-OH, NCT00878644) or in-hospital (THAPCA-IH, NCT00880087); patients were randomized to therapeutic hypothermia or therapeutic normothermia. The primary outcome, survival with favorable 12-month neurobehavioral outcome (Vineland Adaptive Behavior Scales [VABS-II]), did not differ between treatment groups in either trial. Neurologists examined 181 12-month survivors, described findings using the novel semi-quantitative Pediatric Resuscitation after Cardiac Arrest (PRCA) form, and rated findings in 6 domains; scores ranged from 0 (no deficits) to 21 (maximal deficits). PRCA scores were compared with 12-month VABS-II scores and cognitive scores.
Neurologic outcome PRCA scores were classified as no/minimal impairment, PRCA 0-3, 81/179 (45%); mild impairment, PRCA 4-7, 24/179 (13%); moderate impairment, PRCA 8-11, 15/179 (8%); severe impairment, PRCA 12-16, 20/179 (11%); profound impairment, PRCA 17-21, 39/179 (21%) (2/181 incomplete). VABS-II scores correlated strongly with PRCA category ( = -0.88, < 0.0001, Pearson correlation coefficient) and cognitive scores ( = -0.72, < 0.0001). Factors associated with poor outcomes included out-of-hospital CA, seizure recognition in the early postarrest period, and poor neurologic status at hospital discharge.
The PRCA provides a robust method for depicting neurologic outcomes after acute encephalopathy caused by CA in children. It provides a global semiquantitative rating of neurologic impairment and domain-specific impairment. The strong correlation with well-established neurobehavioral outcome measures supports its validity over a broad age range and wide spectrum of outcomes.
在儿科心脏骤停后治疗性低温(THAPCA)试验中,对 12 个月幸存者实施一种标准化方法来描述神经结局。
两项多中心试验纳入了年龄在 48 小时至 18 岁之间的患儿,这些患儿在院外(THAPCA-OH,NCT00878644)或院内(THAPCA-IH,NCT00880087)发生心脏骤停后仍处于昏迷状态;患者被随机分配到治疗性低温或治疗性常温治疗组。主要结局是存活且 12 个月时神经行为结局良好(适应行为量表第二版[VABS-II]),但这两个试验的治疗组之间并无差异。神经科医生检查了 181 名 12 个月的幸存者,使用新的半定量儿科心脏骤停后复苏(PRCA)表描述发现,并对 6 个领域的发现进行评分;分数范围从 0(无缺陷)到 21(最大缺陷)。PRCA 评分与 12 个月时的 VABS-II 评分和认知评分进行了比较。
神经结局 PRCA 评分被分为无/轻度损伤,PRCA 0-3,81/179(45%);轻度损伤,PRCA 4-7,24/179(13%);中度损伤,PRCA 8-11,15/179(8%);重度损伤,PRCA 12-16,20/179(11%);深度损伤,PRCA 17-21,39/179(21%)(2/181 份不完整)。VABS-II 评分与 PRCA 类别呈强相关性( = -0.88,<0.0001,Pearson 相关系数)和认知评分( = -0.72,<0.0001)。预后不良的相关因素包括院外心脏骤停、早期心脏骤停后癫痫识别和出院时神经状态不良。
PRCA 为儿童因心脏骤停引起的急性脑病后的神经结局提供了一种强大的描述方法。它提供了一种对神经损伤和特定领域损伤的全球半定量评分。与已建立的神经行为结局测量方法的强相关性支持其在广泛的年龄范围和广泛的结局范围内的有效性。